Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116606 | 0.82 | ALDH1A1 (0.69) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| SCHEMBL5800828 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| SCHEMBL388181 | 0.82 | ALDH1A1 (0.69) | ALDH1A1CYP3A4CYP19A1NQO2CYP1A1 | |
| SCHEMBL811852 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CYP19A1NQO2CYP1A1 | |
| Ammonia Solution, Strong SCHEMBL10988442 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| SCHEMBL30365875 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| Hydrochloric Acid SCHEMBL3275940 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| SCHEMBL21611343 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| SCHEMBL1629471 | 0.76 | TP53 (0.52) | ALDH1A1CYP3A4TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL10174930 | 0.76 | GRIN2D (0.36) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189060-B1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PF MEDICAMENT (FR) | 2018-06-20 | — | — | EP | disclosed |
| US-20170281622-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| EP-3189060-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | Pierre Fabre Médicament (FR) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034634-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
| EP-2419428-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-8722687-B2 | Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy | ASTEX THERAPEUTICS LTD (GB) | 2014-05-13 | — | — | US | disclosed |
| EP-2419428-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | Astex Therapeutics Ltd. (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2010119285-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| EP-1171127-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | Targacept, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6337351-B1 | AROMATIC OLEFIN AMINES | TARGACEPT, INC. | 2002-01-08 | — | — | US | disclosed |
| US-6310102-B1 | OXY OR HYDROXY OR NITRO SUBSTITUTED PHENYLALKYLENE AMINE DERIVATIVE USED FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER CHARACTERIZED BY AN ALTERATION IN NORMAL NEUROTRANSMITTER RELEASE | TARGACEPT, INC. | 2001-10-30 | — | — | US | disclosed |
| US-6262124-B1 | FOR ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS, FOR EXAMPLE, AS AGONISTS OF SPECIFIC NICOTINIC RECEPTOR SUBTYPES; FOR THERAPY OF DYSFUNCTION OF THE CENTRAL AND AUTONOMIC NERVOUS SYSTEMS | TARGACEPT, INC., A CORPORATION OF DELAWARE | 2001-07-17 | — | — | US | disclosed |
| WO-2001017943-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000078708-A1 | SUBSTITUTED BENZAMIDE INHIBITORS OF RHINOVIRUS 3C PROTEASE | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| US-6166048-A | Pharmaceutical compositions for inhibition of cytokine production and secretion | TARGACEPT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1042274-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000023418-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | FGFR1, FGFR3, FGFR2 | ALDH1A1 475/4885CYP3A4 862/4885TDP1 1661/4885 |
| US-20170281622-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | JAK2, JAK3, JAK1 | ALDH1A1 3818/4885CYP3A4 3794/4885TDP1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.